10-Q: Atomera Reports Q2 Loss Amid R&D Spend, ATM Dilution

Atomera Incorporated reported increased net losses and minimal revenue for Q2 2025, continuing to rely on at-the-market equity offerings for liquidity while addressing internal control weaknesses.

Summary

• Atomera Incorporated, an early-stage semiconductor technology company, reported a net loss of $4.967 million for the three months ended June 30, 2025, compared to $4.361 million for the same period in 2024.
• Revenue for Q2 2025 was approximately $0, a significant decrease from $72,000 in Q2 2024, primarily from MSTcad licensing and consulting services.
• Year-to-date net loss for the six months ended June 30, 2025, was $10.176 million, up from $9.183 million in the prior year period.
• Operating expenses increased to $5.193 million in Q2 2025 from $4.628 million in Q2 2024, driven by higher research and development costs.
• Research and development expenses rose by 16% to $3.004 million in Q2 2025, mainly due to increased device fabrication costs, employee costs, and stock-based compensation.
• The company had cash and cash equivalents of $22.026 million and working capital of $20.0 million as of June 30, 2025.
• Atomera entered into a new Equity Distribution Agreement (2025 ATM) on May 27, 2025, to sell up to $50.0 million of common stock.
• During Q2 2025, approximately 185,000 shares were sold via the 2025 ATM, generating $792,000 in net proceeds at an average price of $5.21 per share.
• Year-to-date, the company sold 349,000 shares through ATM offerings, yielding $3.2 million in net proceeds at an average price of $9.89 per share.
• Subsequent to June 30, 2025, an additional 393,000 shares were issued through the ATM offering, raising approximately $2.0 million in net proceeds at an average price of $5.23 per share.
• Management concluded that disclosure controls and procedures were not effective as of June 30, 2025, due to a material weakness in controls over journal entry review and approval.

Sentiment

Score: 3

Explanation: The sentiment is negative due to zero revenue in the quarter, increased net losses, continued cash burn, and the disclosure of a material weakness in internal controls. While the new ATM facility provides liquidity, it comes at the cost of shareholder dilution, and the company remains in a pre-commercialization phase with significant future capital requirements.

Positives

• Secured a new $50.0 million at-the-market (ATM) equity distribution agreement, providing continued access to capital.
• Maintained a cash and cash equivalents balance of $22.026 million and working capital of $20.0 million as of June 30, 2025, which management believes is sufficient for at least the next 12 months.
• Increased interest income to $234,000 in Q2 2025 from $185,000 in Q2 2024, reflecting higher interest rates on cash and investments.
• Reduced selling and marketing expenses by 32% in Q2 2025 and 52% year-to-date, primarily due to headcount reductions, indicating cost management efforts in this area.

Negatives

• Reported zero revenue for the three months ended June 30, 2025, a significant decline from $72,000 in the prior year period.
• Experienced an increased net loss of $4.967 million in Q2 2025, compared to $4.361 million in Q2 2024.
• Accumulated deficit grew to $231.696 million as of June 30, 2025, from $221.520 million at December 31, 2024.
• Cash and cash equivalents decreased to $22.026 million from $25.778 million at the end of 2024.
• Continued to incur significant operating losses and negative cash flow from operations, with $8.287 million used in operating activities year-to-date.
• Disclosure controls and procedures were deemed not effective as of June 30, 2025, due to a material weakness in internal controls over journal entry review and approval.
• Ongoing reliance on equity offerings (ATM) for funding, leading to continued shareholder dilution.

Risks

• Ability to successfully commercialize MST technology and generate sufficient revenue from license fees and royalties.
• Exposure to competing technological and market developments in the semiconductor industry.
• Need to enter into collaborations with other companies or acquire technologies to enhance or complement current offerings.
• Risk of being unable to secure additional capital if current funds are insufficient, potentially requiring curtailment of R&D and further cost reductions.
• Material weakness in internal controls over financial reporting related to the review and approval of journal entries, which could adversely affect the ability to record, process, summarize, and report financial information accurately.
• Reliance on a single operating segment, making the company vulnerable to challenges within the semiconductor technology licensing market.
• Potential for further shareholder dilution due to ongoing at-the-market equity offerings.

Future Outlook

Management believes that available capital is sufficient to fund current business plans and obligations for at least 12 months from the filing date. Future capital requirements depend on successful commercialization of MST technology, market developments, and the need for collaborations or technology acquisitions. If sufficient revenue from license fees and royalties is not generated in a timely manner, additional capital will be required, potentially through ATM offerings, follow-on equity offerings, debt financing, or joint ventures. The company may also consider alternatives to its current business plan or be required to curtail R&D and reduce costs to conserve cash if unable to secure additional capital.

Management Comments

• "Based on the funds it has available as of the date of the filing of this report, the Company believes that it has sufficient capital to fund its current business plans and obligations over, at least, 12 months from the date that these financial statements have been issued."
• "The Company's future capital requirements and the adequacy of its available funds will depend on many factors, including the Company's ability to successfully commercialize its technology, competing technological and market developments, and the need to enter into collaborations with other companies or acquire technologies to enhance or complement its current offerings."
• "If we are not able to generate sufficient revenue from license fees and royalties in a timeframe that satisfies our cash needs, we will need to raise more capital."
• "In the event we require additional capital, we will endeavor to acquire additional funds through various financing sources, including our ATM, follow-on equity offerings, debt financing and joint ventures with industry partners."
• "We will consider alternatives to our current business plan that may enable us to achieve revenue-producing operations and meaningful commercial success with a smaller amount of capital."
• "If we are unable to secure additional capital, we may be required to curtail our research and development initiatives and take additional measures to reduce costs in order to conserve cash."

Industry Context

Atomera operates in the highly competitive and capital-intensive semiconductor industry, specifically focusing on proprietary performance enhancement technologies like Mears Silicon Technology (MST). The industry is characterized by continuous innovation and the need for greater performance and lower power consumption in integrated circuits. As an early-stage company with limited revenue, Atomera's success is heavily dependent on its ability to secure commercial licensing agreements with major foundries, IDMs, and fabless manufacturers. The broader industry trend towards smaller, more efficient transistors creates a market need for Atomera's additive and low-cost MST technology, but commercial adoption remains a critical hurdle. The company's reliance on ATM offerings for funding is common for early-stage technology firms in this sector, highlighting the significant investment required before widespread commercialization and profitability.

Comparison to Industry Standards

• Atomera's revenue of $0 for Q2 2025 and $4,000 year-to-date is significantly below established semiconductor IP licensing companies like ARM Holdings (now part of SoftBank), which generates billions in licensing and royalty revenue annually. This highlights Atomera's early-stage commercialization phase.
• The company's recurring operating losses and negative cash flow from operations are typical for pre-commercialization technology development firms, but the lack of substantial revenue growth indicates a slower-than-expected market penetration compared to successful IP firms that scale rapidly once key design wins are achieved.
• The reliance on at-the-market equity offerings for liquidity is a common financing strategy for small-cap technology companies with high R&D burn rates and limited revenue, similar to many biotech or early-stage software companies, but it results in significant shareholder dilution.
• The identified material weakness in internal controls over financial reporting is a governance concern that deviates from best practices for publicly traded companies, regardless of size, and is a red flag for investors compared to more mature industry players with robust control environments.

Corporate Governance

Related Party Transactions

• On April 28, 2024, the Chief Executive Officer, Scott Bibaud, purchased 2,247 shares of common stock at a price of $4.45 per share, totaling approximately $10,000.

Stakeholder Impact

• Shareholders: Experience continued dilution from at-the-market equity offerings and face ongoing losses, impacting share value. The material weakness in internal controls may also erode investor confidence.
• Employees: Benefit from stock-based compensation plans, but headcount reductions in selling and marketing indicate potential for further organizational adjustments.
• Customers/Partners: Continued R&D investment and licensing efforts aim to provide advanced semiconductor solutions, but the company's financial instability could be a concern for long-term partnerships.
• Creditors: The company's recurring losses and reliance on equity raises for liquidity may pose higher risk, though current cash position is deemed sufficient for 12 months.

Next Steps

• Continue efforts to commercialize MST technology and secure additional licensing agreements.
• Address and remediate the identified material weakness in internal controls over the review and approval of journal entries.
• Monitor and manage cash burn, potentially through further cost reductions if revenue generation does not accelerate.
• Explore additional financing sources, including equity offerings, debt financing, and joint ventures, if current capital proves insufficient.
• Continue research and development activities to enhance MST technology and related offerings like MSTcad.

Key Dates

Recommendation

The company exhibits significant financial weakness with zero revenue in the quarter, increasing net losses, and consistent cash burn from operations. While the new ATM facility provides short-term liquidity, it comes at the cost of substantial shareholder dilution. The disclosed material weakness in internal controls is a serious governance concern, indicating potential risks in financial reporting reliability. As an early-stage company, Atomera's commercialization remains highly uncertain, and its continued reliance on capital raises without a clear path to profitability makes it a high-risk investment. A seasoned investor would likely view these factors as strong indicators to sell or avoid the stock, especially given the lack of tangible commercial progress.

Keywords

Semiconductor, MST, Mears Silicon Technology, Licensing, Integrated Circuits, Foundries, IDMs, Fabless, Technology Development, 10-Q, Financial Results, Capital Raise, Internal Controls